Autosomal dominant polycystic kidney disease: the changing face of clinical management
- PMID: 26090645
- DOI: 10.1016/S0140-6736(15)60907-2
Autosomal dominant polycystic kidney disease: the changing face of clinical management
Erratum in
-
Department of Error.Lancet. 2015 Jun 27;385(9987):2576. doi: 10.1016/S0140-6736(15)61160-6. Lancet. 2015. PMID: 26122160 No abstract available.
Abstract
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although first reported 500 years ago, this disorder is still regarded as untreatable and its pathogenesis is poorly understood despite much study. During the past 40 years, however, remarkable advances have transformed our understanding of how the disease develops and have led to rapid changes in diagnosis, prognosis, and treatment, especially during the past decade. This Review will summarise the key findings, highlight recent developments, and look ahead to the changes in clinical practice that will likely arise from the adoption of a new management framework for this major kidney disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous